文献速递淋巴瘤造血干细胞移植与细胞治疗

治疗前代谢肿瘤体积与霍奇金淋巴瘤CD30 CAR-T细胞治疗反应相关

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

本研究在27例复发难治经典型霍奇金淋巴瘤患者中评估CD30 CAR-T细胞治疗后的相关因素,中位随访9.5个月,17例(63%)进展,中位无进展生存期352天;淋巴清除及输注前高代谢肿瘤体积(>60 mL)与更差的无进展生存期相关。

要点

  • CD30 CAR-T治疗复发难治经典型霍奇金淋巴瘤后63%患者进展。
  • 淋巴清除及输注前MTV>60 mL与更差的无进展生存期相关。
  • 桥接治疗、CAR-T扩增/持久性及CD3+PD-1+淋巴细胞比例未显示与PFS相关。

核心结论

  • 淋巴清除及CD30 CAR-T输注前高基线代谢肿瘤体积(>60 mL)与复发难治经典型霍奇金淋巴瘤患者更差的无进展生存期相关。

研究设计与样本

  • 研究纳入27例接受淋巴清除和CD30 CAR-T细胞治疗的复发难治经典型霍奇金淋巴瘤患者,评估临床及相关因素与无进展生存期的关系。

主要发现

  • 中位随访9.5个月,17例(63%)进展,中位无进展生存期352天(95%CI:116-未达到),2例(7%)死亡,中位总生存期未达到。
  • 接受桥接治疗、对桥接治疗的反应、CD30 CAR-T扩增/持久性以及治疗前6周CD3+PD-1+淋巴细胞百分比与无进展生存期差异无关。

关键数值与推荐

  • 高代谢肿瘤体积阈值:>60 mL(淋巴清除及CD30 CAR-T输注前测量)。
  • 无进展生存期:中位352天(95%CI:116-未达到)。
  • 进展比例:17/27(63%);死亡比例:2/27(7%)。

临床怎么用

  • 对于计划接受CD30 CAR-T治疗的复发难治经典型霍奇金淋巴瘤患者,淋巴清除及输注前高代谢肿瘤体积(>60 mL)可能提示更差的无进展生存期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observed in a subset of patients. The objective of this study was to characterize clinical and correlative factors associated with progression-free survival (PFS) after CD30.CAR-T cell therapy. We evaluated correlatives in 27 patients with r/r cHL treated with lymphodepletion and CD30.CAR-T cells. With a median follow-up of 9.5 months, 17 patients (63%) progressed, with a median PFS of 352 days (95% confidence interval: 116-not reached), and 2 patients died (7%) with a median overall survival of not reached. High metabolic tumor volume (MTV, >60 mL) immediately before lymphodepletion and CD30.CAR-T cell infusion was associated with inferior PFS (log rank, P = .02), which persisted after adjusting for lymphodepletion and CAR-T dose (log rank, P = .01 and P = .006, respectively). In contrast, receiving bridging therapy, response to bridging therapy, CD30.CAR-T expansion/persistence, and percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy were not associated with differences in PFS. In summary, this study reports an association between high baseline MTV immediately before lymphodepletion and CD30.CAR-T cell infusion and worse PFS in patients with r/r cHL. This trial was registered at www.clinicaltrials.gov as #NCT02690545.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Voorhees TJ, Zhao B, Oldan J, et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022. PMID: 34666347. doi:10.1182/bloodadvances.2021005385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。